Search
Proteasome subunit beta type-10
go.drugbank.com/bio_entities/BE0004738TargetHumansThe proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-depe...
Polypeptides: Proteasome subunit beta type-10Synonyms: Low molecular mass protein 10Keratin, type I cytoskeletal 10
go.drugbank.com/bio_entities/BE0009062TargetHumansStructural component of intermediate filaments in suprabasal keratinocytes of stratified epithelia. Forms heteropolymers primarily with the type II keratin KRT1, and also with KRT2, assembling into intermediate filament networks that sup...
Polypeptides: Keratin, type I cytoskeletal 10Synonyms: CK-10, Keratin-10Serine/threonine-protein kinase 10
go.drugbank.com/bio_entities/BE0009541TargetHumansSerine/threonine-protein kinase involved in regulation of lymphocyte migration. Phosphorylates MSN, and possibly PLK1. Involved in regulation of lymphocyte migration by mediating phosphorylation of ERM proteins such as MSN. Acts as a neg...
Polypeptides: Serine/threonine-protein kinase 10Interleukin-10 receptor subunit beta
go.drugbank.com/bio_entities/BE0014312TargetHumansShared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. ...
Polypeptides: Interleukin-10 receptor subunit betaSynonyms: IL-10 receptor subunit beta, Interleukin-10 receptor subunit 2Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigationalBlocking the interaction of TSLP with the receptors TSLPR and IL-7Rα improves asthma-associated biomarkers including eosinophil counts and IgE, FeNO, IL-5, and IL-13 levels. … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.
Synonyms: AMG 157, AMG-157Categories: Amino Acids, Peptides, and ProteinsMitogen-activated protein kinase 10
go.drugbank.com/bio_entities/BE0001097TargetHumansSerine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. Extracellular stimuli such as pro-inflammatory cytokines or physical stress stimulate the...
Polypeptides: Mitogen-activated protein kinase 10Synonyms: MAPK 10, MAP kinase 10Carbonic anhydrase-related protein 10
go.drugbank.com/bio_entities/BE0003631TargetHumansDoes not have a catalytic activity
Polypeptides: Carbonic anhydrase-related protein 10Inclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigational[A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia … [A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia
Categories: Nucleic Acids, Nucleotides, and Nucleosides, Compounds used in a research, industrial, or household settingProducts: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 MLDiazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigationalIn September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates. … Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.
Synonyms: 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxideCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: LORBRENA® 100 MG, LORVIQUA (TABLETS 100 MG)